Mazdutide Peptide · Research brief

Mazdutide Peptide: Research Overview, Purity Data and Where to Buy

Real Peptides Research TeamEditorial

Updated October 14, 202611 min read

55 WORDS

Short answer

Most research peptides in the incretin family hit one receptor and stop there. Mazdutide doesn't. It's a synthetic analogue built on the oxyntomodulin scaffold, engineered to engage the GLP-1 receptor and the glucagon receptor at the same time, which is why the mazdutide literature reads differently from the single-target papers most labs are used to.

Key takeaways

Mazdutide is a lipidated oxyntomodulin analogue that activates both the GLP-1 receptor and the glucagon receptor, and it is also indexed under IBI362 and LY3305677.
HPLC purity and net peptide content are two different measurements, and a 99% purity figure says nothing about how much peptide the vial actually holds.
Freeze-thaw cycling degrades peptides in solution faster than almost any other handling error, which is why single-use aliquots are standard practice.
Mazdutide is not approved by the FDA for any indication, and regulatory progress in another jurisdiction does not alter the research-use-only status of material sold in the U.S.
Mass spectrometry confirms identity, because HPLC alone cannot distinguish a correct sequence from a clean-running deletion sequence.
A certificate of analysis without a matching lot number is documentation theatre. The lot on the vial must appear on the certificate.

Our team synthesises and screens research-grade peptides in small batches, and the questions we field about mazdutide are almost never about receptor pharmacology. They're about identity, purity, counterion content, and whether the certificate on file actually matches the vial in the freezer. All products are sold for laboratory research use only and are not for human consumption.

What is mazdutide?

Mazdutide (also indexed as IBI362 and LY3305677) is a lipidated peptide analogue of oxyntomodulin that acts as a dual GLP-1 receptor and glucagon receptor agonist. Published research on mazdutide examines cardiometabolic signalling, energy expenditure pathways and hepatic glucose handling. It is supplied to laboratories as a lyophilised powder and is not an approved drug in the United States.

The common over-simplification is that mazdutide is just 'a GLP-1 peptide'. It isn't, strictly. The glucagon receptor arm is the entire design intent of the molecule, and it's what separates it from semaglutide-class compounds in both pharmacology and published endpoints. This hub covers what the molecule is, what the indexed literature examines, how laboratories handle and store it, how per-lot purity is verified, and where mazdutide can be sourced for research.

A dual agonist built on the oxyntomodulin scaffold

Mazdutide is a fatty-acid-modified peptide analogue of oxyntomodulin, a naturally occurring gut hormone that binds both the GLP-1 receptor (GLP-1R) and the glucagon receptor (GCGR). That dual activity is the design intent, not a side effect. Developed by Innovent Biologics under license from Eli Lilly, mazdutide carries two earlier identifiers that still dominate the older literature: IBI362 and LY3305677.

The mechanism in plain terms: GLP-1R activation in research models drives glucose-dependent insulin secretion, slows gastric emptying and engages hypothalamic satiety signalling. GCGR activation does something close to the opposite on paper. It raises hepatic glucose output, yet it also increases energy expenditure and influences hepatic lipid handling. Balancing those two arms is the pharmacological problem mazdutide was built around, and much of the published work is an exploration of where that balance lands.

The lipidation matters just as much. Attaching a fatty acid chain to a peptide backbone promotes reversible albumin binding, which slows renal clearance and extends circulating half-life. That's the structural reason mazdutide is studied on a weekly schedule in clinical research rather than a daily one. Our team sees the same structural logic across the lipidated analogue class: the backbone sets the receptor profile, the side chain sets the pharmacokinetics.

What the published literature examines

The indexed literature on mazdutide runs from early-phase pharmacology through late-stage clinical reporting, and the full set is viewable on PubMed. Research suggests the dominant themes are cardiometabolic: glycaemic markers, body weight endpoints, hepatic fat content, lipid parameters, blood pressure, and tolerability profiles dominated by the gastrointestinal adverse events typical of the incretin class.

Here's the literature-search mistake we see constantly, and it costs people entire phases of evidence: searching only the generic name. A large share of the early mazdutide work was published while the compound was still called IBI362 or LY3305677, so a search on IBI362 returns reports that the generic-name query alone can miss. Run all three terms before concluding the evidence base is thin.

Two further characteristics shape how the mazdutide literature should be read. First, the bulk of published clinical cohorts are adults in China, which matters for external validity when comparing against multinational trial programs for other incretin peptides. Second, the trial program names, reported under the GLORY and DREAMS banners, are the fastest way to track related publications across journals.

We won't quote efficacy figures here. Trial numbers get paraphrased and distorted within two reposts, and for a research audience the primary source is the only version worth reading.

Laboratory handling and storage basics

Lyophilised mazdutide is stable as a dry powder under cold, dark, desiccated conditions, typically at or below −20°C for long-term storage, with short transit excursions at ambient temperature generally tolerated because the lyophilised state removes the water that drives hydrolysis and aggregation. Once a peptide goes into solution, that protection is gone.

In solution, standard laboratory practice for peptides in this class is refrigerated storage at 2–8°C for short working periods and −20°C or below for longer holds, protected from light. Repeated freeze-thaw cycling is the quiet killer: each cycle creates ice-crystal shear and local concentration gradients that promote aggregation, so single-use aliquots beat one repeatedly opened vial every time.

Three handling details matter more than most lab notes admit. Lipidated peptides like mazdutide are surface-active, so adsorption to glass and untreated polypropylene can quietly reduce what's actually in solution. Low-bind consumables help. Vigorous vortexing shears peptide chains and introduces air; gentle swirling until the cake dissolves is the standard. And letting a vial equilibrate to room temperature before opening prevents condensation from pulling moisture into residual powder.

No measurement arithmetic belongs on a hub page like this. Quantities used in any experiment are the researcher's call, documented against their own institutional protocols, not something a supplier should imply. Mazdutide supplied for research arrives sealed as a lyophilised powder with its lot documentation.

How purity is verified, lot by lot

Purity on a peptide certificate of analysis means one specific thing: the area-percent of the main peak on reverse-phase HPLC, usually read at 214 nm or 220 nm where the peptide bond absorbs. A mazdutide lot reported at 99% or higher HPLC purity is telling you that 99% of the UV-absorbing material eluting from that column is the target species. It is not telling you how much peptide is in the vial.

That distinction is where most sourcing decisions go wrong. Purity and net peptide content are separate measurements. A vial can be 99% pure and still hold meaningfully less peptide by mass than the label weight, because lyophilised powder also carries residual water and counterions, commonly trifluoroacetate from purification or acetate after salt exchange. Karl Fischer titration quantifies water; amino acid analysis or nitrogen determination quantifies true peptide content. Ask for both, not just the purity line.

Identity is the third leg. Mass spectrometry (ESI-MS or MALDI-TOF) confirms the observed molecular weight against the theoretical mass for the mazdutide sequence, which is what separates a correctly assembled chain from a deletion sequence that still runs clean on HPLC.

Every mazdutide lot we release ships against its own certificate, with the chromatogram and mass spectrum published rather than summarised. The certificates of analysis library is open to read before anyone commits to a lot.

Regulatory status and what research-use-only actually means

Mazdutide is not approved by the U.S. Food and Drug Administration for any indication, and it is not a dietary supplement, a compounded medicine, or a veterinary product. In the United States it moves exclusively as a research compound for in vitro and laboratory investigation. All products are sold for laboratory research use only and are not for human consumption.

Outside the U.S., mazdutide has progressed through late-stage clinical development and regulatory review in China, where Innovent Biologics has led the program. Regulatory progress in one jurisdiction does not change the status of research-grade material sold elsewhere. An approved finished drug product is manufactured, released and labelled under an entirely separate regime from research-use-only peptide supplied to a laboratory, and conflating the two is the most common misreading of mazdutide's status we encounter.

Research-use-only labelling carries obligations on the buying side too. Material is intended for qualified researchers working under appropriate institutional oversight, and handling, documentation and disposal fall under the receiving laboratory's own policies. Anyone with questions about animal health should raise them with a licensed veterinarian, because research peptides are not veterinary medicines and should never be treated as one.

The information here is educational. It describes what the published literature reports and how laboratories handle material. It is not administration guidance of any kind.

Where to buy mazdutide for laboratory research

Buying research-grade mazdutide comes down to four verifications, and price is not one of them. First, a per-lot certificate of analysis with the lot number printed on both the certificate and the vial label, because a generic representative certificate for a compound tells you nothing about the material in your freezer. Second, the raw analytical output: the HPLC chromatogram and mass spectrum, not a typed summary table. Third, synthesis transparency, since small-batch synthesis with verified amino-acid sequencing limits the lot-to-lot drift that wrecks reproducibility across a long study. Fourth, shipping practice, including insulated or cold-chain packing and a stated policy for shipments delayed in transit.

Our mazdutide product page lists the lyophilised material we supply alongside its lot documentation, and the wider peptide catalogue is organised the same way. We've reviewed this pattern across hundreds of laboratory customers, and the finding is consistent: suppliers who publish full chromatograms get asked fewer questions, because the answer is already on the page.

How dual agonists compare with single-target incretin peptides

This table maps receptor profiles and literature focus across four research peptides that get cross-compared constantly. It covers pharmacology and evidence base only, with no efficacy figures, because paraphrased trial numbers are the fastest route to a wrong conclusion.

Research peptide	Receptor targets	Literature focus	Bottom line for researchers
Mazdutide (IBI362, LY3305677)	GLP-1R and GCGR dual agonist on an oxyntomodulin scaffold	Cardiometabolic endpoints, hepatic fat, energy expenditure signalling; published cohorts concentrated in China	Relevant when the research question involves the glucagon receptor arm; search all three compound names to capture the full evidence base
Tirzepatide	GIP receptor and GLP-1R dual agonist	Glycaemic and body-weight endpoints across large multinational programs	The best-characterised dual agonist, but GIP and GCGR are entirely different pharmacological questions
Semaglutide	GLP-1R single agonist	The deepest and longest-running incretin evidence base	The default comparator for any GLP-1 arm, not a substitute for dual-agonist work
Retatrutide	GIP, GLP-1R and GCGR triple agonist	Earlier-stage published record, smaller indexed set	Useful where both GIP and glucagon arms matter; expect a thinner literature than mazdutide currently has

What If: Research Sourcing Scenarios

What if a lyophilised vial arrives warm?

Record the condition on receipt and contact the supplier before opening it. Lyophilised peptides tolerate short ambient excursions far better than material in solution, because removing water removes the primary route to hydrolysis and aggregation. That tolerance isn't unlimited, and the variable that matters is time at temperature, not whether the box felt cold on arrival. A supplier who can state the pack-out method and transit duration is giving you data; one who simply says it's fine is not.

What if a certificate of analysis has no lot number?

Treat it as a marketing document rather than analytical data. A certificate is only meaningful when the lot number on it matches the number printed on the vial you received, because purity, water content and counterion residue vary batch to batch even under identical synthesis conditions. Representative certificates reused across every shipment of mazdutide tell you what a good lot once looked like, and nothing about yours. Published per-lot records exist precisely so a buyer can check before committing.

What if lot-to-lot variation shows up mid-study?

Compare certificates side by side before changing anything at the bench. Differences in net peptide content, residual water or counterion identity between mazdutide lots can shift experimental results with no change in the HPLC purity figure, which is exactly why content data matters as much as the purity line. Where a study spans months, reserving material from a single synthesis batch removes the variable entirely. Teams running long projects report that batch reservation is the cheapest reproducibility insurance available to them.

The Unglamorous Truth About Peptide Sourcing

Here's the honest answer: the quality gap between research peptide suppliers is almost never visible in the product photo, the website design, or the purity number on the label. It shows up in the paperwork. Two vials of mazdutide can both claim 99% purity, carry different net peptide content, different residual water and different counterion load, and behave differently in the same assay. The only way to see that before the experiment runs is to read the chromatogram and the content data for your specific lot. Suppliers who don't publish them usually aren't hiding anything. They just never generated the data.

Researchers comparing options across the catalogue can read the published per-lot analytics in our certificate of analysis library, browse the full research peptide range, or review how we approach high-purity synthesis before selecting a compound for a study.

Mazdutide occupies an unusual position in the research peptide world right now: a molecule with a genuinely distinct receptor profile, a clinical record concentrated in one region, and a generic name that only recently replaced the two development codes most of its early literature was filed under. That combination means the fastest way to get the science wrong is to treat it as interchangeable with the GLP-1 peptides it superficially resembles. The glucagon arm is the whole story. All products are sold for laboratory research use only and are not for human consumption.

References

Peer-reviewed sources on Mazdutide indexed in PubMed, listed for research context. Real Peptides supplies Mazdutide for laboratory research use only.

Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials. Diabetes, obesity & metabolism, 2026. PMID 41804840. doi:10.1111/dom.70643
Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis. Diabetes, obesity & metabolism, 2026. PMID 42410325. doi:10.1111/dom.71058
Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Frontiers in endocrinology, 2024. PMID 38440786. doi:10.3389/fendo.2024.1309118
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature, 2026. PMID 41407860. doi:10.1038/s41586-025-10031-z
Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature, 2026. PMID 41407859. doi:10.1038/s41586-025-10026-w
Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA, 2026. PMID 42251595. doi:10.1001/jama.2026.8142
Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial. Contemporary clinical trials, 2026. PMID 41260459. doi:10.1016/j.cct.2025.108150
Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes. Expert opinion on therapeutic patents, 2026. PMID 41820018. doi:10.1080/13543776.2026.2645812

Questions

Mazdutide is a lipidated peptide analogue of oxyntomodulin that acts as a dual agonist at the GLP-1 receptor and the glucagon receptor. In research models, the GLP-1 arm is associated with glucose-dependent insulin secretion, slowed gastric emptying and satiety signalling, while the glucagon arm is associated with hepatic glucose output, energy expenditure and hepatic lipid handling. It is supplied to laboratories as a lyophilised powder for research use only.

Yes. IBI362 and LY3305677 are development codes for the same molecule now generically named mazdutide, developed by Innovent Biologics under license from Eli Lilly. A large share of the earlier published pharmacology is indexed under those codes rather than the generic name, so a literature search should include all three terms to capture the complete evidence base.

Research-use-only peptides are intended for qualified researchers, laboratories and institutions working under appropriate oversight. They are not sold for human or veterinary consumption, and they are not dietary supplements or compounded medicines. The receiving laboratory is responsible for handling, documentation and disposal under its own institutional policies.

At minimum, a certificate of analysis tied to the specific lot number printed on the vial, including the reverse-phase HPLC chromatogram and the mass spectrometry identity confirmation. Net peptide content and water content figures are the two most commonly omitted data points and the two most worth asking for. Our certificates of analysis are published per lot so they can be reviewed before ordering.

Standard practice for lyophilised peptides in this class is cold, dark and desiccated storage at or below −20°C, with the vial allowed to equilibrate to room temperature before opening to avoid condensation. Once in solution, peptides are typically held at 2–8°C for short working periods or frozen for longer holds, protected from light. Repeated freeze-thaw cycling promotes aggregation, so single-use aliquots are preferred over one repeatedly opened vial.

Both are dual agonists, but they target different receptor pairs. Mazdutide engages the GLP-1 receptor and the glucagon receptor on an oxyntomodulin scaffold, while tirzepatide engages the GIP receptor and the GLP-1 receptor. That makes them pharmacologically distinct research tools rather than substitutes, and the published literature for each reflects different endpoint priorities and different trial populations.

No. Mazdutide is not approved by the U.S. Food and Drug Administration for any indication, and material supplied in the United States is research grade for laboratory investigation only. Development and regulatory review have advanced furthest in China, where Innovent Biologics leads the program, but approval status in another jurisdiction does not change how research-use-only material is classified or sold elsewhere.

No, and this is the most misunderstood line on any certificate. HPLC purity reports the area-percent of the main peak among UV-absorbing species eluting from the column, not the mass fraction of peptide in the powder. Lyophilised material also contains residual water and counterions such as trifluoroacetate or acetate, so net peptide content measured by amino acid analysis or nitrogen determination is a separate figure you should request.

The practical risks are analytical rather than dramatic: temperature excursions in transit, aggregation from freeze-thaw cycling, loss to surface adsorption on untreated plasticware, and lot-to-lot variation that shifts results without any visible change in purity. Each is manageable with documented receipt conditions, single-use aliquots, low-bind consumables and side-by-side certificate comparison between lots.

Per-lot certificates, including chromatograms and mass spectra, are published in our certificate of analysis library and are readable before purchase. Match the lot number on the certificate to the number printed on the vial label when the shipment arrives. If a supplier only offers a representative certificate with no lot number, that document cannot tell you anything about the material you actually received.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA